PEN — Penumbra, Inc. stock price, charts and financials

QT43Penumbra, Inc.

Penumbra, Inc. (NYSE: PEN) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
326.04
+1.38+0.43%
PENQT43Penumbra, Inc.·NYSE
326.04+0.43%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E79.38EPS (ttm)4.09Insider Own3.76%Shs Outstand39.39MPerf Week1.08%
Market Cap12.79BForward P/E53.34EPS next Y6.09Insider Trans-0.17%Shs Float38.29MPerf Month2.11%
Enterprise Value12.80BPEG11.69EPS next Q-Inst Own-Short Float5.55%Perf Quarter0.00%
Income161.13MP/S8.50EPS this Y18.31%Inst Trans-Short Ratio4.86Perf Half Y-5.07%
Sales1.50BP/B8.34EPS next Y26.41%ROA8.13%Short Interest2.12MPerf YTD4.42%
Book/sh-P/C45.95EPS next 5Y18.73%ROE11.09%52W High363.97 -10.42%Perf Year35.28%
Cash/sh-P/FCF59.23EPS past 3/5Y-ROIC8.40%52W Low222.20 46.73%Perf 3Y20.49%
Dividend Est.-EV/EBITDA57.57Sales past 3/5Y18.35% 20.18%Gross Margin67.84%Volatility0.62% 0.61%Perf 5Y21.95%
Dividend TTM-EV/Sales8.50EPS Y/Y TTM1030.56%Oper. Margin12.45%ATR (14)2.24Perf 10Y373.68%
Dividend Ex-Date-Quick Ratio3.86Sales Y/Y TTM25.94%Profit Margin10.67%RSI (14)66.49Recom2.59
Dividend Gr. 3/5Y-Current Ratio5.75EPS Q/Q-1.20%SMA201.47%Beta0.69Target Price347.00
Payout0.00%Debt/Eq0.14Sales Q/Q15.04%SMA501.82%Rel Volume0.60Prev Close324.66
Employees4,700LT Debt/Eq0.14EarningsNov 04SMA2002.28%Avg Volume397.13KPrice326.04
IPO DateSep 18, 2015Option/ShortYes / YesEPS/Sales Surpr.-21.02% 1.16%Net Debt/EBITDA0.03Volume239,493Change0.43%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-06-26ReiteratedEvercore ISI GroupOutperform$335$320
May-07-26ReiteratedEvercore ISI GroupOutperform$360$335
Feb-26-26ReiteratedUBSBuy$335$374
Jan-20-26DowngradeCanaccord GenuityBuyHold$359$374
Jan-20-26DowngradeRBC CapitalOutperformSector Perform$355$374
Jan-16-26ReiteratedRobert W. Baird$345$374
Jan-16-26DowngradeLeerink PartnersOutperformMarket Perform$263$374
Jan-16-26DowngradeTruist SecuritiesBuyHold$370$374
Jan-16-26DowngradeCitigroupBuyNeutral
Jan-16-26DowngradeNeedhamBuyHold
Latest News
Aug-06-26
Jul-30-26
Jul-25-26
Jul-24-26
Jul-23-26
Jul-22-26
Jul-20-26
Jul-14-26
Jul-07-26
Jun-22-26
Jun-18-26
Jun-17-26
Company

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,5051,4041,195
Cost of Goods Sold Incl. D&A483461440
Gross Profit1,020942755
Selling, General and Administrative Excl. Other742663574
Research and Development929095
Other Operating Expense
000
Operating Income18718986
Interest Expense011
Unusual Expense
Non-Operating Income (Expense)1817-64
Net Income Before Taxes20420521
Income Taxes42277
Consolidated Net Income16117814
Net Income From Continuing Operations16117814
Net Income16117814
EPS (Recurring)4.094.570.36
EPS (Basic, Before Extraordinaries)4.094.570.36
EPS (Diluted)4.074.520.36
EBITDA22222446
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio80.1168.79659.67
Price To Sales Ratio8.458.647.75
Gross Margin67.7767.0963.18
Operating Margin12.4313.467.20
Net Margin10.7012.681.17
Shares Outstanding393939
Market Capitalization12,71612,1259,262
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$379.48$335.97$292.47$248.97$205.46 Close Price0.00M2.90M5.80M8.70M11.61MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Grewal HarpreetDirectorApr 02 '26Sale328.2210032,8228,719Apr 06
Yuen MaggieChief Financial OfficerMar 02 '26Sale342.302,432832,47418,353Mar 04
Grewal HarpreetDirectorJan 06 '26Sale312.6418658,1518,230Jan 08
Wilder ThomasDirectorJan 02 '26Sale310.7218657,7940Jan 06
Bose AraniDirectorDec 11 '25Sale308.8215,0004,632,293258,462Dec 15
Roberts JohannaEVP, Gen. Counsel & SecretaryDec 05 '25Sale300.1330090,03963,836Dec 09
Grewal HarpreetDirectorDec 02 '25Sale292.9810029,2988,416Dec 03
Roberts JohannaEVP, Gen. Counsel & SecretaryDec 01 '25Sale294.94600176,96764,136Dec 03
Roberts JohannaEVP, Gen. Counsel & SecretaryNov 25 '25Sale300.061,800540,10864,736Nov 26
Bose AraniDirectorNov 25 '25Sale300.197,5002,251,425275,261Nov 26
Bose AraniDirectorNov 21 '25Sale290.567,5002,179,213282,761Nov 25
Roberts JohannaEVP, Gen. Counsel & SecretaryNov 10 '25Sale266.98600160,18963,657Nov 12
Grewal HarpreetDirectorNov 04 '25Sale227.5818642,3308,516Nov 06
Grewal HarpreetDirectorOct 02 '25Sale248.6118646,2418,702Oct 03
Roberts JohannaEVP, Gen. Counsel & SecretaryOct 01 '25Sale249.70600149,82264,257Oct 03
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.